TrialHaematologica2017

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.

Dominik Selleslag et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.